***** MIRAVANT ***** Continue Phase III von SnET2 - 500 Beiträge pro Seite

[xoma]

Miravant wird Phase III SnET2 weiterführen !

Die Aktie ist vom Jahreshoch bei 10,70 Euro eingebrochen
auf 1,40 Euro, nachdem die ersten Resultate nicht sehr aussichtsreich waren.

Vielleicht wird es mit neuen Studien besser, ich denke in den nächsten Tagen wird sie mächtig aufholen. Im Moment ist sie bei +20%.

MIRAVANT ANNOUNCES SPENDING REDUCTION PROGRAM

SANTA BARBARA, Calif., January 23, 2002 - Miravant Medical Technologies (Nasdaq: MRVT) today announced a cost restructuring program to reduce overhead costs and streamline operations while continuing to progress the company`s key development programs. This restructuring is designed to lower the company`s annual projected net operational cash burn rate.

"These reductions are appropriate in light of our current funding environment and will allow us to sustain our ongoing development programs," said Gary S. Kledzik, Ph.D., chairman and chief executive officer. "We are committed to continue advancing Miravant`s pipeline of new generation drugs, which represent potential licensing opportunities."

Miravant`s current business status is as follows:

With appropriate spending adjustments, including cash on hand plus funding due under our existing agreements with Pharmacia Corporation, Miravant has current operating capital for approximately 9 - 12 months. Miravant has financed its operations and development programs over the last 12 years through various sources and is exploring additional funding opportunities going forward.


In ophthalmology, Miravant and Pharmacia are continuing to analyze phase III clinical results for our first-generation drug SnET2 in age-related macular degeneration. Future development plans for the drug will be determined after completion of the analyses.

In dermatology, the company is focusing its efforts to accelerate patient accrual in the phase II clinical trial of PhotoPoint™ MV9411. Investigators are enrolling approximately 54 patients in the drug and light dose escalation study for plaque psoriasis, a chronic skin disease affecting approximately 5 million Americans.

In cardiovascular disease, Miravant continues to generate positive results in preclinical studies for restenosis and atherosclerosis. Results of studies with lead drug PhotoPoint MV0633 will be presented in early February at the Cardiovascular Radiation Therapy Conference, Washington D.C.

[xoma]

Gestern über +56% an der Nasdaq, das wurde auch Zeit, nachdem sich der Kurs seit dem Einbruch im Januar nur noch nach unten bewegt hat.

[xoma]

Das war also der Grund:

Miravant Regains Rights to PhotoPoint SnET2

15:33 EST Tuesday, March 05, 2002
Business Editors & Health/Medical Writers
SANTA BARBARA, Calif.--(BW HealthWire)--March 5, 2002--Miravant Medical Technologies (Nasdaq:MRVT) announced today that it has terminated certain contractual relationships with Pharmacia Corporation, including the Ophthalmology Development and License Agreement and other related contracts for proprietary drug SnET2. Miravant regained the rights to all assets related to the SnET2 phase III clinical trials for age-related macular degeneration (AMD), including the full clinical data package.
In addition, Miravant restructured the credit agreement in which Pharmacia reduced the outstanding debt from approximately $27 million to $10 million. In connection with the debt reduction, Miravant will re-assume lease obligations for the SnET2 manufacturing facility and will forego the remaining $3.2 million line-of-credit.
Gary S. Kledzik, Ph.D., chairman and chief executive officer, stated, "Now that we`re back in control of the drug SnET2, we`re excited about gaining access to all clinical data in order to conduct a thorough, in-depth analysis of the results. Ophthalmology continues to be our primary focus, and we will aggressively pursue all options available to us for SnET2 and our new PhotoPoint(TM) drug compounds."
The SnET2 assets returned to Miravant include the Investigational New Drug (IND) application, preclinical and clinical data, inventories of active pharmaceutical ingredient and finished dose formulation, drug manufacturing rights, manufacturing equipment and clinical laser devices.
Full details of the agreements are contained in Miravant`s Form 8-K to be filed this week with the Securities and Exchange Commission.
Miravant Medical Technologies specializes in both pharmaceuticals and devices for photoselective medicine. The company is developing its proprietary PhotoPoint photodynamic therapy (PDT) in ophthalmology, dermatology, cardiovascular disease and oncology. Miravant Cardiovascular, Inc. is investigating intravascular PhotoPoint PDT for the treatment of angioplasty-related restenosis and atherosclerosis.
The statements above by Dr. Kledzik regarding the company conducting a thorough analysis of clinical data and aggressively pursuing all options in ophthalmology for SnET2 and new PhotoPoint drug compounds, are forward-looking and relate to our future plans, objectives, expectations and intentions. Our actual results may differ materially from those described in these statements. For instance, the occurrence of one or more of the following may cause our results to differ from our plans: the company`s operating capital may not be sufficient to continue operations and/or sustain its current development programs; the company may not complete a thorough analysis of SnET2 phase III data; the company may decide not to or be unable to further develop SnET2 for AMD or any other indication; and/or the company may decide not to or be unable to further develop its new PhotoPoint drug compounds. For a discussion of additional important risk factors that may cause our results to differ from those described above, please refer to our annual report on Form 10-K for the year ended December 31, 2000 and other quarterly and periodic reports filed with the Securities and Exchange Commission.
For more information please visit our web site at: www.miravant.com.
Copyright © 2001, Business Wire

[Schockeins]

BW0168 AUG 27,2002 6:01 PACIFIC 09:01 EASTERN


( BW)(CA-MIRAVANT-MEDICAL)(MRVT) Miravant Updates SnET2 Phase III
Clinical Results for Macular Degeneration

Business Editors & Health/Medical Writers

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Aug. 27, 2002--Miravant
Medical Technologies (OTCBB:MRVT), a pharmaceutical development
company specializing in PhotoPoint(TM) photodynamic therapy (PDT),
announced today further results of a comprehensive analysis of the
SnET2 phase III clinical data. Two drug doses of SnET2 (0.5mg/kg and
0.75mg/kg) were investigated for the treatment of wet age-related
macular degeneration (AMD), also called sub-foveal choroidal
neovascularization (CNV), a disease characterized by abnormal blood
vessel growth at the back of the eye. Patients who enrolled in the
clinical study had a wide range of baseline visual acuity and were
retreated only upon disease progression. As previously reported, SnET2
did not achieve the primary efficacy endpoint when all patients were
included in the top-line analysis. However, we now report that certain
subsets of patients demonstrated stabilized or improved visual acuity
at 2 years:

-- 65.6% of patients treated 3 times over 2 years at the lower
drug dose maintained stable vision compared to 39.3% of
placebo patients; of these, patients with better than 20/200
baseline vision and study compliant lesion size demonstrated
63.2% stable vision compared to 25.0% placebo.

-- In a small subset of occult only CNV patients, 67.7% of
patients treated at the lower drug dose sustained stable
vision compared to 40% placebo.

-- Angiography data for these subsets as well as the total
patient population confirmed that treated patients had a
marked reduction in lesion area and leakage relative to
placebo.

Gary S. Kledzik, Ph.D., chairman and chief executive officer,
stated, "Age-related macular degeneration is a complex disease, and we
now know that the response to treatment can be affected by a number of
variables, such as baseline visual acuity, lesion size and classic and
occult disease components. While the vision of the overall placebo
group remained surprisingly stable, we are encouraged by the positive
treatment results in the responding subsets, which affirms our
confidence in PhotoPoint SnET2."
"We are also very excited by the treatment response in occult only
patients, as occult disease remains a very significant unmet medical
need and represents at least 60% of the overall AMD opportunity,"
added Dr. Kledzik. "The angiography data support our belief that
PhotoPoint can be a useful therapy for targeting abnormal blood
vessels in various diseases of the eye. Now that we have largely
completed the data analysis, we intend to request a meeting with the
Food and Drug Administration to discuss the phase III clinical
results. We are currently vigorously pursuing a strategic partnering
relationship for this drug in ophthalmology."

Top line results of all patients

Overall, of the two investigated drug doses, the lower dose (0.5
mg/kg) demonstrated better results in both safety and efficacy.

Safety Observations -

-- PhotoPoint treatments at both drug doses were well tolerated.

-- The incidence of serious adverse events was similar among the
treatment and placebo groups.

-- There were 4 serious adverse events considered
treatment-related: 3 reports of drug extravasation (discharge
into surrounding tissue at the infusion site) and 1 report of
allergic reaction.

-- Incidence of photosensitivity adverse events in the 0.5 mg/kg
cohort was 9.7% vs. 2.7% for the placebo. None of the
photosensitivity events was considered serious.

Efficacy Observations -

-- Patients in the 0.5 mg/kg group received an average of 2.35
treatments during the 2-year study.

-- A substantial percentage, 59.0% of the 0.5 mg/kg treated
patients maintained stable vision at 2 years (loss of less
than 3 lines on a standardized eye chart).

-- 28.4% of the 0.5 mg/kg treated patients maintained baseline or
showed improved visual acuity at 2 years.

-- Despite the very encouraging results in the treated patient
population and the low number of retreatments required in the
study, 50.8% of the overall placebo group maintained stable
visual acuity over the 2-year period, while 23.0% maintained
baseline or showed improved visual acuity. Statistical
significance in visual acuity between treated patients and
placebo was not achieved in the total study population.

-- Fluorescein angiography data showed a marked reduction in
lesion area and leakage in the treated group relative to the
placebo group throughout the 2-year study.

Dr. Kledzik added, "The stable visual acuity of the overall
placebo group was unexpected relative to previously published
ophthalmology studies. We now believe that the number of patients
entering the study with already severe vision loss was an important
contributing factor in the placebo stability."

Results of subset analysis

-- A subset of all patients receiving 3 treatments in the 0.5
mg/kg cohort demonstrated a statistically significant response
of stable vision compared to placebo patients receiving 3
treatments: 65.6% vs. 39.3% placebo (p=0.0189).

-- Of patients receiving three 0.5mg/kg treatments, those having
protocol-compliant baseline lesion size and baseline visual
acuity greater than 31 letters (better than 20/200 vision)
showed a statistically significant response at 2 years: 63.2%
vs. 25.0% placebo (p=0.0008).

-- A small subset of patients was enrolled with occult only CNV,
rather than some component of classic CNV as specified in the
clinical protocol. In the responding occult group, 67.7% of
0.5 mg/kg treated patients sustained stable vision at 2 years
vs. 40% placebo (p=0.1213).

-- Angiography data for these subsets showed a marked reduction
in lesion area and leakage in drug treated patients relative
to placebo patients throughout the 2-year study.

Design of SnET2 phase III clinical trials

The clinical trials consisted of two identical, randomized,
double-masked, placebo-controlled studies evaluating two SnET2 drug
doses with a single light dose. The SnET2 doses were 0.5 mg/kg (372
patients) and 0.75 mg/kg (365 patients) relative to placebo (183
patients). The 920 patients enrolled in the intent to treat population
had a wide range in baseline visual acuity (approximately 20/500 to
20/40). Patients were administered either SnET2 or placebo followed by
light treatment. Retreatments were based on fluorescein angiography
and/or changes in visual acuity, as evaluated by the investigators
every 3 months. The primary efficacy endpoint was the proportion of
patients losing less than 15 letters (3 lines on a standardized eye
chart) of visual acuity at 2 years, which was considered stable
vision. CNV closure (shutdown of leaking blood vessels beneath the
retina) as determined by fluorescein angiography was a secondary
endpoint.

About AMD

AMD, the leading cause of severe vision loss in people over 50
years of age, is a degenerative disease of the macula -- the point on
the retina that enables sharp, straight-ahead central vision. The wet
form of AMD is the more severe type, involving the growth of small,
leaky blood vessels (CNV) beneath the macula. While the wet form
affects only 10 percent of AMD patients, it accounts for 90% of the
blindness caused by the disease. There are approximately 400,000 new
cases of wet AMD each year in the U.S. and Europe. The components of
wet AMD known as classic and occult are based on different patterns of
CNV leakage seen on fluorescein angiography.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is
a specialty pharmaceutical company focused on PhotoPoint(TM)
photodynamic therapy (PDT), a family of medical procedures based on
drugs that are activated by light. The company is committed to the
discovery and development of proprietary photoselective drugs and
innovative light devices for licensing to global pharmaceutical and
medical device companies. Miravant is developing PhotoPoint PDT for
serious diseases in ophthalmology, dermatology, cardiovascular disease
and oncology.

The statements above by Dr. Kledzik and other statements about
positive treatment results, PhotoPoint use as a vascular targeting
therapy, meeting with the Food and Drug Administration, and a
corporate partnering relationship in ophthalmology are forward-looking
and relate to our future plans, objectives, expectations and
intentions. Our actual results may differ materially from those
described in these statements. For instance, the occurrence of one or
more of the following may cause our results to differ from our plans:
the company`s operating capital may not be sufficient to continue some
or all of its development programs and operations; upon completion of
the full analysis of the phase III AMD clinical data, the company may
decide not to further develop SnET2 for AMD or any other indication;
discussions with potential corporate partners may not materialize or
may not provide the funding and support we need; PhotoPoint may not
prove useful as a vascular targeting agent, and we may decide not to
or be unable to further develop our new generation PhotoPoint drugs in
ophthalmology, dermatology, cardiovascular disease and/or oncology.
For a discussion of additional important risk factors that may cause
our results to differ from those described above, please refer to our
annual report on Form 10-K for the year ended December 31, 2001 and
other quarterly and periodic reports filed with the Securities and
Exchange Commission. Our products require regulatory approval before
marketing, sales or clinical use. PhotoPoint is a trademark of
Miravant Medical Technologies.

--30--AMP/la WAM/la

CONTACT: Miravant Medical Technologies
Tom Herrick, 805/685-9880

[Schockeins]

BW0099 AUG 29,2002 6:01 PACIFIC 09:01 EASTERN


( BW)(CA-MIRAVANT-MEDICAL)(MRVT) Miravant Raises $2.5 Million in
Equity Financing

Business Editors

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Aug. 29, 2002--Miravant
Medical Technologies (OTCBB:MRVT), a pharmaceutical development
company specializing in PhotoPoint(TM) photodynamic therapy (PDT),
announced today that it has closed a round of new financing consisting
of the sale of unregistered shares of common stock for $2.5 million at
$0.50 per share, based on a premium of approximately 20% of the
average closing price for the prior 10 trading days. For every two
common shares acquired, the equity purchase includes a warrant for one
share priced at $0.50. A group of private investors participated in
the offering. The proceeds will be used for research, development and
general corporate purposes.
Gary S. Kledzik, Ph.D., chairman and chief executive officer,
stated, "We are pleased to secure this additional operating capital
while we continue discussions with potential corporate partners. Our
goal is to raise further funding through development collaborations
and licensing of PhotoPoint SnET2 and other promising drugs in our
pipeline. We will address future equity financings as needed to assure
that our disease programs are adequately funded."

Details of the equity financing are contained in Miravant`s Form
8-K expected to be filed with the Securities and Exchange Commission
(SEC) on September 3, 2002.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is
a specialty pharmaceutical company focused on PhotoPoint(TM)
photodynamic therapy (PDT), a family of medical procedures based on
drugs that are activated by light. The company is committed to the
discovery and development of proprietary photoselective drugs and
innovative light devices for licensing to global pharmaceutical and
medical device companies. Miravant is developing PhotoPoint PDT for
serious diseases in ophthalmology, dermatology, cardiovascular disease
and oncology.
For more information, please visit our web site at:
www.miravant.com.

The statements above by Dr. Kledzik regarding the company`s
discussions with potential corporate partners, co-development and
licensing agreements for PhotoPoint drugs, and additional equity
financings are forward-looking and relate to our future plans,
objectives, expectations and intentions. Our actual results may differ
materially from those described in these statements. For instance, the
occurrence of one or more of the following may cause our results to
differ from our plans: our operating capital may not be sufficient to
continue some or all of our development programs and operations; there
is no guarantee that we will be successful in obtaining future
financing at all or on favorable terms from potential corporate
partners and/or other investors; and we may decide not to or may be
unable to continue some or all of our PhotoPoint development programs
in ophthalmology, dermatology, cardiovascular disease and/or oncology.
For a discussion of additional important risk factors that may cause
our results to differ from those described above, please refer to our
annual report on Form 10-K for the year ended December 31, 2001, our
report on Form 10-Q ended June 30, 2002, and other quarterly and
periodic reports filed with the Securities and Exchange Commission.
The company`s products require regulatory approval prior to marketing,
sales or clinical use. PhotoPoint(TM) is a trademark of Miravant
Medical Technologies.

--30--mtb/la hb/la mra/la bf/la jap/la mw/la

CONTACT: Miravant Medical Technologies
Tom Herrick, 805/685-9880 (Investor Relations)

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICAL MEDICAL DEVICES PHARMACEUTICAL
SOURCE: Miravant Medical Technologies

[Schockeins]

Neuigkeit von HEUTE!!!
BW0156 SEPT 05.2002 6:30 PAZIFIK 09:30 ÖSTLICH


(Bw)(ca-miravant)(mrvt) Miravant empfängt VEREINIGTE STAATEN Patent für in hohem Grade starke Kategorien der Licht aktivierten Drogen; Patent bedeckt Dermatologie-Droge MV9411 jetzt Phase II in den klinischen Versuchen für Psoriasis

Geschäft Editors/Health U. Medizinische Verfasser

SANKT BARBARA, Calif. -- (BUSINESS WIRE) -- Sept.. 5, 2002 -- Miravant medizinische Technologien (OTCBB:MRVT), eine pharmazeutische Verwertungsgesellschaft, die auf PhotoPoint(TM) die photodynamic Therapie (PDT) sich spezialisiert, daß es herausgegebenes VEREINIGTE STAATEN Patent Nr. 6.444.914, ein gewesen ist Aufbau des Angelegenheit Patents in bezug auf photoreactive (Licht aktiviert) Mittel heute verkündet, die Indium als der zentrale Metallkern enthalten. Das Patent liefert ausgedehnte Deckung einer Reihe zusammengesetzter Kategorien, die in hohem Grade stark in vorgerückten preclinical Modellen gewesen sind. Sind aktuelle Droge PhotoPoint MV9411, jetzt Phase II in den klinischen Versuchen für behandelndes Plakette psoriasis und PhotoPoint MV6401, Miravants die preclinical Onkologiedroge enthalten, die vor kurzem veröffentlicht wird in zwei Abdeckung Artikeln des überragenden Journals "Krebsforschung." Byron C. Robinson, Ph.D., Direktor Miravants Chemieforschung und Produktentwicklung, sagte, "der Kraft der Mittel, die durch dieses Patent abgedeckt werden, ist erheblich grösser als andere PDT Drogen. Sie haben die Fähigkeit, biologische Antworten im wesentlichen unterere Droge und helle Dosen und so verringern zu den Behandlungzeiten und zum Potential für Nebenwirkungen zu erzielen."

[Schockeins]

Neuigkeit von Heute!!!
Dr. Robinson verweist ein komplettes Chemieforschung und - Entwicklungsprogramm, das große Bibliotheken der photoreactive Mittel erzeugt hat, die entworfen werden, um Krankheitgewebe selektiv zu zielen. Miravant jetzt besitzt oder hat exklusive weltweite Rechte zu 6 VEREINIGTEN STAATEN und zu fremden pharmazeutischen Patenten, herausgegeben oder erlaubt, die ausgedehnte Kategorien der photoreactive Mittel umfassen. Die Dermatologiedroge MV9411 Miravants, abgedeckt durch dieses Patent, wird in eine eigene Formulierung für leistungsfähigen Hautdurchgriff vorbereitet. Die Droge wird in einer Multi-centerphase II Droge- und Lichtdosiseskalation Studie geprüft und zielt 54 Patienten mit chronischem Hautkrankheit-Plakette psoriasis. Auch bedeckt durch dieses Patent, erzielte unser Onkologiedrogeanwärter MV6401, nachgeforscht in einem preclinical orthotopic Brustkrebsmodell, nicht nur Zerstörung der Brustkrebs-Tumorzellen aber auch die simultane Zerstörung der anormalen Tumor$blutgefässe, die ihr Wachstum stützen.

[Schockeins]

Neues v0m 20.09.02:
BW)(CA-MIRAVANT)(MRVT) Miravant`s Intracoronary PhotoPoint PDT to Be
Presented at Vulnerable Plaque Symposium, TCT 2002

Business Editors & Health/Medical Writers
TCT 2002

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Sept. 20, 2002--

PhotoPoint Preclinical Studies Show Favorable Results for
Prevention of Restenosis and Treatment of Atherosclerosis

Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical
development company specializing in PhotoPoint photodynamic therapy
(PDT), announced today that PhotoPoint cardiovascular research results
will be presented next week at the Transcatheter Cardiovascular
Therapeutics (TCT) meeting, September 24-28, Washington D.C. Ron
Waksman, M.D. of Georgetown University Medical School and Washington
Hospital Center will present preclinical results for prevention of
intracoronary restenosis and treatment of atherosclerotic plaque on
Friday, September 27, at two scientific symposia: "Vulnerable Plaque:
Emerging Diagnostic and Therapeutic Modalities" and "Innovative
Devices and Futuristic Therapies." In addition to the symposia, three
poster abstracts describing PhotoPoint preclinical data will be
presented at the scientific session on September 25.
Robert W. Scott, M.D., president of subsidiary Miravant
Cardiovascular, Inc., said, "I am extremely proud of our
cardiovascular scientific program and the quality of the data that we
are presenting at the prestigious TCT conference, one of the most
important international meetings in interventional cardiology. We are
making significant progress leveraging PhotoPoint technology across
multiple indications in restenosis, atherosclerosis and vulnerable
plaque. We will continue to gain momentum and expand our network of
medical and scientific collaborators at this meeting."

PhotoPoint PDT Results

In comprehensive studies to be presented at TCT, Intracoronary
PhotoPoint PDT has demonstrated excellent preclinical efficacy in
restenosis. Optimized in a swine coronary artery vascular injury
restenosis model, PhotoPoint PDT gives a selective, uniform biological
response confined to target cells, media and adventitia. Target
tissues demonstrate greater than 75% acellularity (removal of cells)
with no evidence of post-treatment thrombosis (blood clots),
inflammation or weakening of vessel walls. The treated arterial
segments eventually repopulate with normal cells after healing of the
vascular injury. This dosimetry has allowed us to demonstrate
inhibition of angioplasty or stent induced restenosis with a favorable
safety profile in chronic studies.
In atherosclerosis models using the same dosimetry, PhotoPoint PDT
has demonstrated depletion of plaque cell populations, depletion of
inflammatory cells (macrophages) and favorable mechanical effects on
treated segments of vessel walls. Rupture of unstable atherosclerotic
plaques, called vulnerable plaque (VP), is now considered to be one of
the main causes of thrombosis and sudden catastrophic death from heart
attacks and strokes. The PhotoPoint endovascular light treatment
catheter is compatible with emerging optical imaging techniques for VP
detection. Thus, PDT appears to be ideally positioned for treatment of
VP.
Dr. Waksman is Clinical Professor Medicine (Cardiology),
Georgetown University Medical Center; Associate Director, Division of
Cardiology, Washington Hospital Center; and Director of Experimental
Angioplasty and Vascular Brachytherapy for the Cardiovascular Research
Institute.
The scientific poster abstracts for the TCT 2002 meeting and other
cardiovascular presentations are posted at www.miravant.com.

About PhotoPoint PDT

Miravant`s Intravascular / Intracoronary PhotoPoint PDT uses a
light-activated drug that localizes in vessel walls and abnormal
plaques. The drug is activated by non-thermal, non-ionizing light
delivered to the target site via a robust, guidewire-compatible
catheter with the potential to treat multi-vessel disease, focal and
diffuse lesions. PhotoPoint PDT is in late-stage preclinical
investigation for in-stent restenosis, atherosclerosis and vulnerable
plaque, and for hemodialysis vascular access graft stenosis.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is
a specialty pharmaceutical company focused on PhotoPoint(TM)
photodynamic therapy (PDT), a family of medical procedures based on
drugs that are activated by light. The company is committed to the
discovery and development of proprietary photoselective drugs and
innovative light devices for licensing to global pharmaceutical and
medical device companies. Miravant is developing PhotoPoint PDT for
serious diseases in ophthalmology, dermatology, cardiovascular disease
and oncology.

The statements above by Dr. Scott about making progress and
gaining momentum in cardiovascular programs and leveraging PhotoPoint
technology into multiple indications, and other statements about
preclinical efficacy and safety in restenosis, atherosclerosis and
vulnerable plaque are forward-looking and relate to our future plans,
objectives, expectations and intentions. Our actual results may differ
materially from those described in these statements. For instance, the
occurrence of one or more of the following may cause our results to
differ from our plans: preclinical test results may not be indicative
of clinical results when and if clinical trials are initiated; we may
not successfully complete the clinical trial process and we may be
unable to prove that our products are safe and efficacious; our
operating capital may not be sufficient to continue some or all of our
development programs and operations; and we may decide not to or may
be unable to continue some or all of our PhotoPoint development
programs in ophthalmology, dermatology, cardiovascular disease and/or
oncology. For a discussion of additional important risk factors that
may cause our results to differ from those described above, please
refer to our annual report on Form 10-K for the year ended December
31, 2001, our report on Form 10-Q for the quarter ended June 30, 2002
and other quarterly and periodic reports filed with the Securities and
Exchange Commission. The company`s products require regulatory
approval prior to marketing, sales or clinical use. PhotoPoint(TM) is
a trademark of Miravant Medical Technologies.

--30--JAP/la mra/la hb/la

CONTACT: Miravant Medical Technologies
Tom Herrick, 805/685-9880 (Investor Relations)

[Schockeins]

Hallo was glaubt IHR von Miravant !!?
Haben wir den Boden gefunden?
Bleiben wir bis Jahresende seitwärts?
Sie wollen ja zurück zur NAS!!?
Bitte um Antworten!!

[Schockeins]

NEWS:






Market News

--------------------------------------------------------------------------------

MRVT MIRAVANT MEDICAL TECHNOLOGIES

--------------------------------------------------------------------------------

All Penny Stocks Covers MRVT

TUESDAY , OCTOBER 01, 2002 11:44 AM

According to the All Penny Stocks web page, Miravant Medical Technologies (OTCBB: MRVT) is a stock to watch.

MRVT is a specialty pharmaceutical company focused on PhotoPoint(TM) Photodynamic Therapy.

MRVT has a current price of $0.74000 per share.

After going over their Disclosure/Disclaimer statement, Knobias was unable to determine whether or not All Penny Stocks was compensated.







--------------------------------------------------------------------------------

Copyright © 2002. The Nasdaq Stock Market, Inc
Copyright ©2002 Knobias.com, LLC

[Schockeins]

Total Share Volume 1,424,444

--------------------------------------------------------------------------------

GSCO
GOLDMAN, SACHS & CO. 388,523 1 27 - - - 388,523 5 7
NITE
KNIGHT SECURITIES, L.P. 384,723 2 27 530,233 2 26 1,695,938 1 32
SCHB
SCHWAB CAPITAL MARKETS L.P. 162,633 3 11 425,995 3 21 785,473 3 15
GVRC
GVR COMPANY LLC 120,898 4 8 42,843 9 2 163,741 7 3
BAMM
BROKERAGEAMERICA, INC 70,800 5 4 9,480 10 <1 85,280 10 1
MLNJ
HERZOG, HEINE, GEDULD, LLC 60,890 6 4 169,047 4 8 516,012 4 9
PUGS
PUGLISI & CO. 60,700 7 4 5,000 11 <1 65,700 12 1
NEUB
NEUBERGER BERMAN, LLC 50,600 8 3 86,650 5 4 185,075 6 3
MHMY
M. H. MEYERSON & CO., INC. 38,900 9 2 52,800 7 2 91,700 9 1
WIEN
WIEN SECURITIES CORP. 32,217 10 2 1,600 13 <1 33,817 13 <1
HILL
HILL THOMPSON MAGID, L.P. 15,310 11 1 45,700 8 2 122,710 8 2
INCA
INSTINET CORPORATION 9,500 12 <1 800 15 <1 13,300 15 <1
MSCO
MORGAN STANLEY & CO., INCORPORATED 5,800 13 <1 60,244 6 3 81,744 11 1
NATL
NATIONAL SECURITIES CORPORATION 5,600 14 <1 - - - 5,600 16 <1
FRAN
WM. V. FRANKEL & CO., INCORPORATED 5,000 16 <1 5,000 11 <1 20,600 14 <1
FLTT
FLEET TRADING/A DIVISION OF FLEET SECURITIES 4,500 17 <1 - - - 4,500 18 <1
PGON
PARAGON CAPITAL MARKETS, INC. 2,500 18 <1 2,000 12 <1 4,500 18 <1

--------------------------------------------------------------------------------

[Schockeins]

Miravant operates on a fiscal year ending December 31st. Our quarterly reporting period ends on March 31st, June 30th, September 30th, and December 31st. Earnings releases are tentatively scheduled for March 14, May 9, August 8 and November 12, 2002.

[Schockeins]

MRVT - MIRAVANT MED TECHS
Page of 1

October 2002 September 2002 Year-to-Date
Volume Rank % Volume Rank % Volume Rank %

--------------------------------------------------------------------------------

Total Share Volume 853,586

--------------------------------------------------------------------------------

NEUB
NEUBERGER BERMAN, LLC 249,430 1 29 50,600 8 3 434,505 5 7
SCHB
SCHWAB CAPITAL MARKETS L.P. 118,275 2 13 162,633 3 11 903,748 2 14
NITE
KNIGHT SECURITIES, L.P. 117,197 3 13 384,723 2 27 1,813,135 1 30
GVRC
GVR COMPANY LLC 102,655 4 12 120,898 4 8 266,396 7 4
HILL
HILL THOMPSON MAGID, L.P. 63,900 5 7 15,310 11 1 186,610 8 3
JEFF
JEFFERIES & COMPANY, INC. 47,090 6 5 - - - 47,090 13 <1
SEAB
SEABOARD SECURITIES, INC. 30,000 7 3 - - - 30,000 16 <1
FLTT
FLEET TRADING/A DIVISION OF FLEET SECURITIES 25,811 8 3 4,500 17 <1 30,311 15 <1
GSCO
GOLDMAN, SACHS & CO. 19,765 9 2 388,523 1 27 408,288 6 6
MLNJ
HERZOG, HEINE, GEDULD, LLC 18,700 10 2 60,890 6 4 534,712 4 8
MHMY
M. H. MEYERSON & CO., INC. 14,600 11 1 38,900 9 2 106,300 9 1
NATL
NATIONAL SECURITIES CORPORATION 10,500 12 1 5,600 14 <1 16,100 18 <1
PUGS
PUGLISI & CO. 8,100 13 <1 60,700 7 4 73,800 12 1
PGON
PARAGON CAPITAL MARKETS, INC. 7,000 15 <1 2,500 18 <1 11,500 20 <1
FRAN
WM. V. FRANKEL & CO., INCORPORATED 5,463 16 <1 5,000 16 <1 26,063 17 <1
TDCM
TD WATERHOUSE CAPITAL MARKETS, INC. 5,000 17 <1 - - - 5,000 22 <1
BAMM
BROKERAGEAMERICA, INC 1,500 18 <1 70,800 5 4 86,780 10 1
WIEN
WIEN SECURITIES CORP. 500 19 <1 32,217 10 2 34,317 14 <1
SILK
SPEAR, LEEDS & KELLOGG, L.P. 100 20 <1 - - - 100 25 <1

--------------------------------------------------------------------------------

[Schockeins]

Q 3 Bericht:
BW0439 NOV 14,2002 10:56 PACIFIC 13:56 EASTERN


( BW)(CA-MIRAVANT)(MRVT) Miravant Announces Third Quarter Results

Business Editors & Health/Medical Writers

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Nov. 14, 2002--Miravant
Medical Technologies (OTCBB:MRVT), a pharmaceutical development
company specializing in PhotoPoint(TM) photodynamic therapy (PDT),
announced consolidated financial results for the third quarter ended
September 30, 2002. Revenues and interest and other income for the
third quarter decreased to $29,000 from $783,000 for the same period
in 2001. The net loss for the quarter was $3.9 million, or $0.19 per
share, compared to a net loss of $4.9 million, or $0.26 per share, for
the same period last year. As of September 30, 2002 the company had
cash and cash equivalents of $2.0 million.
On July 12, 2002, Miravant`s common stock began trading on the OTC
Bulletin Board (OTCBB), effective with its delisting from the Nasdaq
National Market. On August 28th, 2002, the company completed a round
of new financing consisting of the sale of $2.5 million of
unregistered shares of common stock and warrants.
Gary S. Kledzik, Ph.D., chairman and chief executive officer,
said, "In regard to Miravant`s cash position, our plan is to raise
operating capital incrementally while we continue discussions with
potential corporate partners in ophthalmology and other specialties.
During the third quarter, we were pleased to announce encouraging
clinical results of PhotoPoint SnET2 for the treatment of macular
degeneration, after an in-depth analysis of phase III clinical data.
The results show that PhotoPoint performed well in select populations
of patients, stabilizing or improving vision. These findings are
important to Miravant`s future direction, and we are in the process of
discussing them with the FDA."
Dr. Kledzik added, "The work of our cardiovascular team with new
generation drugs is very exciting. Our scientific results support
PhotoPoint`s use as a potential treatment for vulnerable plaque (VP),
probably the largest unmet opportunity in cardiovascular medicine
today. Cardiologists now recognize that the majority of heart attacks
are caused by rupture of this highly unstable form of arterial plaque,
generating intense interest in VP prevention, detection and
treatment."

Scientific Progress

On August 27, 2002, Miravant announced additional safety and
efficacy information for PhotoPoint SnET2 from the phase III clinical
trials for wet age-related macular degeneration, the leading cause of
blindness in older adults. While the drug did not achieve the primary
efficacy endpoint when all patients were included in the top-line
analysis, certain subsets of patients demonstrated stabilized or
improved visual acuity compared to placebo at two years. These
findings were supported by angiography data that showed a marked
reduction in lesion area and leakage in treated patients compared to
placebo-controls throughout the two-year study. Safety observations
were also positive, supporting that the PhotoPoint treatments were
well tolerated.
Miravant`s cardiovascular team moved forward, presenting favorable
preclinical results for PhotoPoint drugs in restenosis and
atherosclerosis/vulnerable plaque at Transcatheter Cardiovascular
Therapeutics (TCT), Washington D.C, a major international conference
held in September. Further results will be presented in November at
the American Heart Association, Chicago.
In dermatology, Miravant continued to enroll patients in a phase
II clinical trial, treating plaque psoriasis patients with topical
drug PhotoPoint MV9411. The study is designed to determine optimal
drug and light dosimetry. Psoriasis is a chronic skin condition with
no known cure, in which the immune system triggers accelerated growth
of the epidermis, causing inflamed, scaly skin plaques.
Miravant is also working in a rapidly growing area of cancer
therapeutics, targeting networks of blood vessels that support the
growth of all solid tumors. PhotoPoint drug MV6401 achieved selective
shutdown of tumor blood vessels and long-term tumor growth delay in an
orthotopic breast tumor model. The company`s oncology research was
published as a cover article in the August 1st issue of Cancer
Research, Miravant`s second such cover article in this prestigious
publication this year.
Adding to Miravant`s extensive intellectual property portfolio,
two new patents were issued during the third quarter. The first is a
composition of matter patent covering a series of compound classes
that have proven to be highly potent in advanced preclinical models,
including dermatology drug MV9411 and oncology drug MV6401. The second
is a very broad method patent covering processes for large-scale
production of photoreactive compounds and their intermediates.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is
a specialty pharmaceutical company focused on PhotoPoint Photodynamic
Therapy (PDT), a family of medical procedures based on drugs that are
activated by light. The company is committed to the discovery and
development of proprietary photoselective drugs and innovative light
devices for licensing to global pharmaceutical and medical device
companies. Miravant is developing PhotoPoint PDT for serious diseases
in ophthalmology, dermatology, cardiovascular disease and oncology.

The statements above by Dr. Kledzik and other statements about
raising additional capital, corporate partnering discussions, SnET2
discussions with FDA and progress in our disease programs are
forward-looking and relate to our future plans, objectives,
expectations and intentions. Our actual results may differ materially
from those described in these statements. For instance, the occurrence
of one or more of the following may cause our results to differ from
our plans: the company`s operating capital may not be sufficient to
continue some or all of its development programs and operations;
additional funding may not be available when needed if at all or under
terms acceptable to the company; upon completion of the full analysis
of the phase III AMD clinical data, the company may decide not to
further develop SnET2 for macular degeneration or any other
indication; the company may be unable to achieve regulatory approvals
for SnET2 or other drugs in development; corporate partnering
relationships may not materialize or may not provide the funding and
support we need; the phase II dermatology clinical trial may prove to
be unsuccessful and/or the trial may not be completed when expected;
the results of the company`s preclinical studies may not be indicative
of future results when and if the clinical trial process begins; and
we may decide not to or be unable to further develop our new
generation PhotoPoint drugs in ophthalmology, dermatology,
cardiovascular disease and/or oncology. For a discussion of additional
important risk factors that may cause our results to differ from those
described above, please refer to our annual report on Form 10-K for
the year ended December 31, 2001 and other quarterly and periodic
reports filed with the Securities and Exchange Commission. Our
products require regulatory approval before marketing, sales or
clinical use. PhotoPoint(TM) is a trademark of Miravant Medical
Technologies.
-0-
*T
Miravant Medical Technologies
Consolidated Statements of Operations (Unaudited)

Three Months Ended Nine Months Ended
9/30/02 9/30/01 9/30/02 9/30/01
------------ --------------------------------------
Revenues:
License-contract
research and
development -- $ 20,000 $ 20,000 $ 224,000
Bulk API sales -- 763,000 479,000 3,049,000
Royalties -- -- -- 75,000
------------ --------------------------------------
Total revenues 783,000 499,000 3,348,000

Cost and expenses:
Cost of goods
sold -- 236,000 479,000 364,000
Research and
development 2,114,000 3,692,000 7,338,000 9,825,000
Selling, general
and
administrative 1,797,000 1,418,000 4,483,000 4,492,000
------------ --------------------------------------
Total costs and
expenses 3,911,000 5,346,000 12,300,000 14,681,000

Loss from
operations (3,911,000) (4,563,000) (11,801,000) (11,333,000)

Interest and other
income (expense):
Interest and
other income 29,000 187,000 147,000 730,000
Interest expense (1,000) (524,000) (282,000) (1,705,000)
Gain on sale of
property, plant
& equipment 10,000 -- 10,000 586,000
------------ --------------------------------------
Total net interest
and other income
(expense) 38,000 (337,000) (125,000) (389,000)
------------ --------------------------------------

Net loss $(3,873,000) $(4,900,000)$(11,926,000)$(11,722,000)
============ ======================================
Net loss per share
- basic and
diluted $(0.19) $(0.26) $(0.61) $(0.63)
============ ======================================
Shares used in
computing net loss
per share 20,580,224 18,670,704 19,450,691 18,612,873
============ ======================================

Selected Consolidated
Balance Sheet Data
As of 9/30/02 As of 12/31/01
------------- --------------
(unaudited)
Cash, cash equivalents, marketable
securities and accounts receivable $ 1,984,000 $ 11,142,000
Total current assets 3,281,000 12,561,000
Total assets 4,953,000 16,123,000

Total current liabilities 6,856,000 3,321,000
Total liabilities 12,504,000 29,963,000
Total stockholders` equity (deficit) (7,551,000) (13,840,000)
Total liabilities and stockholders`
equity (deficit) $ 4,953,000 $ 16,123,000

*T

--30--RJ/la* KH/la MRA/la

CONTACT: Miravant Medical Technologies, Santa Barbara
John Philpott, [phone]
Tom Herrick, [phone] (Investor Relations)

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL DEVICES MEDICAL EARNINGS
SOURCE: Miravant Medical Technologies

[Schockeins]

Neues von 22.11.02
BW0081 NOV 22,2002 6:10 PACIFIC 09:10 EASTERN


( BW)(CA-MIRAVANT)(MRVT) Miravant Signs Letter of Intent for $12
Million Convertible Debt Line of Credit; Company Updates Status of
PhotoPoint SnET2 for Macular Degeneration

Business Editors/Health/Medical Writers

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Nov. 22, 2002--Miravant
Medical Technologies (OTCBB:MRVT), a pharmaceutical development
company specializing in PhotoPoint(TM) photodynamic therapy (PDT),
announced today that it has signed a non-binding letter of intent with
a private party to provide the company a convertible line of credit up
to $12 million. The funds will be available in increments of up to
$1.0 million per month with associated warrants for shares of common
stock. The transaction is subject to the finalization of definitive
documents.
Miravant also disclosed that it is currently in direct discussions
with the U.S. Food and Drug Administration (FDA) to review
comprehensive safety and efficacy data from the completed phase III
clinical trials for PhotoPoint SnET2 to treat wet age-related macular
degeneration (AMD). Over 900 patients participated in two phase III
clinical trials conducted at 59 U.S. ophthalmology centers. Wet AMD is
a degenerative, vision-threatening disease that is the leading cause
of blindness in adults over age 50.
"We are pleased to announce the letter of intent for additional
funding, which I believe can be finalized at desirable terms," said
Gary S. Kledzik, Ph.D. "Regarding our lead drug SnET2, we held a
recent guidance meeting with the FDA that was productive. This was the
first opportunity to lay out the full range of results from in-depth
phase III data analyses, including statistically significant treatment
effects in select patient populations. We are encouraged by these
discussions and the potential to move towards a future filing for
SnET2."

[Schockeins]

Company Symbol Currency Current Recommendation Current Quarter Current Fiscal Year Find out More
Consensus # of Brokers Mean EPS % Change
vs. Yr Ago Mean EPS % Change
vs. Yr Ago
Miravant Medical Technologies MRVT-Q2 (US$) US$ Hold 1 - - - -

[Schockeins]

MRVT MIRAVANT MEDICAL TECHNOLOGIES

--------------------------------------------------------------------------------

VOLUME(+): MRVT Volume 42% > 20-adsv, Stock +12.36%

FRIDAY , DECEMBER 20, 2002 01:46 PM

This is the 2nd VOLUME alert for MRVT in the past 7 calendar days.

Trading for Miravant Medical Technologies (OTCBB: MRVT) has been heavier than usual in today`s session. By 13:45 ET, the stock had already traded 152,900 shares via 63 trades. The cumulative volume is 41.61% above than its 20-day average of 107,975. Normally the stock experiences around 38 individual trades per session.

So far, today`s volume surge has caused a net rise in MRVT`s stock price. At the time of this alert, the stock was trading at $1.000, up $0.110 (+12.36%).

One year ago, the Company`s shares closed at $9.630. The price has declined more than 89 percent since then.

Over the last 10 trading session MRVT has traded in a range between $0.641 and $0.930 and is currently trading 90.20% below its 52-week high of $10.200 set on December 28, 2001 and 426.32% above its 52-week low of $0.190 from July 24, 2002.

In the previous 3 sessions, MRVT trading has displayed a mixed trend. Closing results have been as follows:

December 19, 2002 --- closed at $0.890 up $0.140 (+18.67%) on 199,000 shares
December 18, 2002 --- closed at $0.750 up $0.050 (+7.14%) on 136,100 shares
December 17, 2002 --- closed at $0.700 even for the day on 19,700 shares

The Company last released news on November 22, 2002:

"Miravant Signs Letter of Intent for $12 Million Convertible Debt Line of Credit; Company Updates Status of PhotoPoint SnET2 for Macular Degeneration"

[Schockeins]

MRVT - MIRAVANT MED TECHS
Page of 1

November 2002 October 2002 Year-to-Date
Volume Rank % Volume Rank % Volume Rank %

--------------------------------------------------------------------------------

Total Share Volume 1,675,795

--------------------------------------------------------------------------------

NEUB
NEUBERGER BERMAN, LLC 347,051 1 20 249,430 1 29 781,556 4 10
NITE
KNIGHT SECURITIES, L.P. 260,847 2 15 117,197 3 13 2,073,982 1 26
JEFF
JEFFERIES & COMPANY, INC. 235,900 3 14 47,090 6 5 282,990 8 3
GVRC
GVR COMPANY LLC 159,220 4 9 102,655 4 12 425,616 7 5
SEAB
SEABOARD SECURITIES, INC. 156,800 5 9 30,000 7 3 186,800 11 2
TDCM
TD WATERHOUSE CAPITAL MARKETS, INC. 146,800 6 8 5,000 17 <1 151,800 12 1
MHMY
M. H. MEYERSON & CO., INC. 134,595 7 8 14,600 11 1 240,895 9 3
SCHB
SCHWAB CAPITAL MARKETS L.P. 102,280 8 6 118,275 2 13 1,006,028 2 13
HILL
HILL THOMPSON MAGID, L.P. 50,880 9 3 63,900 5 7 237,490 10 3
GSCO
GOLDMAN, SACHS & CO. 37,737 10 2 19,765 9 2 446,025 6 5
WIEN
WIEN SECURITIES CORP. 15,000 11 <1 500 19 <1 49,317 16 <1
FLTT
FLEET TRADING/A DIVISION OF FLEET SECURITIES 8,935 12 <1 25,811 8 3 39,246 17 <1
BAMM
BROKERAGEAMERICA, INC 5,250 13 <1 1,500 18 <1 92,030 13 1
GNET
GLOBENET SECURITIES, INC. 5,000 14 <1 - - - 10,000 22 <1
RCAP
ROTH CAPITAL PARTNERS, LLC 5,000 14 <1 - - - 5,000 24 <1
FRAN
WM. V. FRANKEL & CO., INCORPORATED 2,500 15 <1 5,463 16 <1 28,563 18 <1
PGON
PARAGON CAPITAL MARKETS, INC. 2,000 16 <1 7,000 15 <1 13,500 20 <1

--------------------------------------------------------------------------------

[Schockeins]

Market News

--------------------------------------------------------------------------------

FNF FIDELITY NATIONAL FINANCIAL, INC.
FNIS FIDELITY NATIONAL INFORMATION SOLUTIONS INC.
MNTR MENTOR CORP.

--------------------------------------------------------------------------------

Few Financial Winners Exist among Santa Barbara County, Calif., Companies

THURSDAY , JANUARY 02, 2003 06:27 PM

Jan 01, 2003 (Santa Barbara News-Press - Knight Ridder/Tribune Business News via COMTEX) -- From Wall Street to State Street, investors bid farewell to a painful year.

Most of Santa Barbara County`s publicly traded companies endured a rougher-than-expected financial ride in 2002.

Only five of 20 county companies enjoyed higher share prices at the end of the year. Others were bruised and battered by the bears.

Optimists may say the beaten-down stock prices for all sorts of companies create lots of opportunities. But it`s going to take awhile for investors to regain confidence in the markets after the Dow Jones suffered its ugliest performance in decades -- declining for the third straight year; the first time that`s happened since 1941.

Winners locally included companies handling real estate and surgical implant products.

Santa Barbara-based Fidelity National Financial and Fidelity National Information Solutions both gained respectable ground.

Fidelity National Financial, the nation`s largest provider of title insurance and real estate-related products and services, benefited nicely from the housing boom. Analysts steadily hiked earnings expectations all year, and the stock went on a tear, jumping from $24.53 at the start of the year to end at $32.83.

Fidelity`s subsidiary company, Fidelity National Information Solutions, also based in Santa Barbara, focuses on providing data and technology solutions to the residential real estate industry. Its shares rose from $10.10 to close at $17.25.

Mentor Corp. in Santa Barbara had a strong year. Its stock jumped from $28.42 in January to close 2002 at $38.50. The company in mid-December declared a two-for-one stock split effective Tuesday. Mentor, first publicly traded more than 30 years ago, deals in a range of medical products including saline-filled breast implants and penile implants.

The only other U.S. maker of breast implants is Inamed Corp. of Goleta. Its shares rose from $29.50 to close the year at $30.80. The company will eliminate 153 jobs at its headquarters this year.

QAD Inc. of Carpinteria didn`t have a great year but its stock inched up from $2.93 per share in January to close at $3.41. Weak software sales took their toll on the firm, which embarked on a cost-cutting program.

Banks had a decent year. Santa Barbara Bank & Trust`s parent company did fine. Shares of Pacific Capital Bancshares started at $28.02 and wound up at $25.45. Mid-State Bank shares opened at $16.42 and closed at $16.27. Community West Bancshares coasted from $5.95 and closed at $4.69.

The telecom dustbowl hit hard. Superconductor Technologies in Goleta saw its share value dragged from $6.50 on Jan. 2 to 94 cents on Dec. 31. Occam Networks in Goleta fell from 40 cents to 7 cents. Somera fell from $7.79 to $2.70.

Santa Barbara-based CKE Restaurants Inc., the operator of Carl`s Jr. and Hardee`s hamburger chains and La Salsa Fresh Mexican Grill chain, saw its shares drop from $9 to $4.30.

Santa Barbara-based Tenet Healthcare collapsed from $59.07 per share to end at $16.40. The company was investigated for overly aggressive pricing and payment collection.

Other results:

Goleta-based Miravant Medical Technologies skidded from $9.61 to 91 cents.

ExperTelligence of Santa Barbara dipped from 24 cents per share to six cents.

Netlojix flattened from 15 cents to two.

Computer Motion dropped from $4.12 to $1.03, although it is well-positioned in the marketplace.

Big Dog Holdings dipped from $3.12 to $2.46.

Deckers Outdoor Corp. dropped from $4.42 to $3.34.

EarthShell Corp. lost about three-quarters of its value, from $2.07 to 58 cents.

By Mark van de Kamp

To see more of the Santa Barbara News-Press, or to subscribe to the newspaper,
go to http://www.newspress.com


(c) 2003, Santa Barbara News-Press, Calif. Distributed by Knight Ridder/Tribune
Business News.

-0-













--------------------------------------------------------------------------------

Copyright © 2002. The Nasdaq Stock Market, Inc
Copyright ©2002 Knobias.com, LLC and Comtex News Network

[Schockeins]

Market News

--------------------------------------------------------------------------------

MRVT MIRAVANT MEDICAL TECHNOLOGIES

--------------------------------------------------------------------------------

VOLUME(+): MRVT Volume 57% > 20-adsv, Stock +25.00%

THURSDAY , JANUARY 16, 2003 01:06 PM

This is the 2nd VOLUME alert for MRVT in the past 7 calendar days.

Trading for Miravant Medical Technologies (OTCBB: MRVT) has been heavier than usual in today`s session. By 13:05 ET, the stock had already traded 200,600 shares via 79 trades. The cumulative volume is 56.85% above than its 20-day average of 127,890. Normally the stock experiences around 37 individual trades per session.

So far, today`s volume surge has caused a net rise in MRVT`s stock price. At the time of this alert, the stock was trading at $1.000, up $0.200 (+25.00%).

One year ago, the Company`s shares closed at $2.090. The price has declined more than 52 percent since then.

Over the last 10 trading session MRVT has traded in a range between $0.600 and $0.940 and is currently trading 53.49% below its 52-week high of $2.150 set on January 17, 2002 and 426.32% above its 52-week low of $0.190 from July 24, 2002.

In the previous 3 sessions, MRVT trading has displayed a mixed trend. Closing results have been as follows:

January 15, 2003 --- closed at $0.800 up $0.040 (+5.26%) on 546,300 shares
January 14, 2003 --- closed at $0.760 down $0.010 (-1.30%) on 186,100 shares
January 13, 2003 --- closed at $0.770 up $0.020 (+2.67%) on 88,500 shares

The Company last released news on November 22, 2002:

"Miravant Signs Letter of Intent for $12 Million Convertible Debt Line of Credit; Company Updates Status of PhotoPoint SnET2 for Macular Degeneration"

[Schockeins]

( BW)(CA-MIRAVANT-MEDICAL-TECH)(MRVT) Miravant to File NDA for Marketing Approval of SnET2 for Wet Macular Degeneration

Business Editors & Health/Medical Writers

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Jan. 30, 2003--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(TM) photodynamic therapy (PDT), today announced plans to file its first New Drug Application (NDA) for marketing approval of PhotoPoint SnET2, a new drug for the treatment of wet age-related macular degeneration (AMD). The company`s decision came after analyses of phase III clinical data showed positive results in a significant number of drug-treated patients versus placebo control patients, and after holding discussions with the Food and Drug Administration (FDA).
"Miravant will seek very competitive labeling claims for PhotoPoint SnET2 in the large AMD market, particularly in regard to the target patient population and the number of treatments required for effectiveness," said Gary S. Kledzik, Ph.D., chairman and chief executive officer. "Positive trends in the phase III clinical data were announced in August 2002 but are now recognized in a much larger group of patients. I believe we have a strong filing package to present to the FDA that supports the safety and efficacy of Miravant`s PhotoPoint treatment for wet AMD."

PhotoPoint SnET2 targets abnormal blood vessels at the back of the eye

Age-related macular degeneration is the leading cause of severe vision loss in people over age 50, a degenerative disease that affects the macula (the point on the retina at the back of the eye that enables sharp, straight-ahead central vision). The wet form of AMD involves the growth of small blood vessels beneath the macula that leak fluid and blood, causing retinal lifting, scarring and loss of central vision. Patients with wet AMD develop a dark shadow in the central field of vision that impairs activities such as reading, driving and recognizing faces.
While the wet form affects only 10 percent of AMD patients, it accounts for 90 percent of the blindness caused by the disease, for which there are few available treatment options. There are approximately 500,000 new cases of wet AMD each year worldwide, with the incidence expected to increase as the population ages.
Miravant`s PhotoPoint SnET2 is a light-activated drug designed to target abnormal blood vessels beneath the macula. By destroying these leaky blood vessels, the retina can potentially return to a more normal architecture.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is a specialty pharmaceutical company focused on PhotoPoint(TM) photodynamic therapy (PDT), a family of medical procedures based on drugs that are activated by light. The company is committed to the discovery and development of proprietary photoselective drugs and innovative light devices for licensing to global pharmaceutical and medical device companies. Miravant is developing PhotoPoint PDT for serious diseases in ophthalmology, dermatology, cardiovascular disease and oncology.
For more information please visit our web site at: www.miravant.com.

The statements above by Dr. Kledzik and other statements about the safety and efficacy of SnET2, filing the NDA for PhotoPoint SnET2 to treat wet AMD and the size of the AMD market are forward-looking and relate to our future plans, objectives, expectations and intentions. Our actual results may differ materially from those described in these statements. For instance, the occurrence of one or more of the following may cause our results to differ from our plans: the company`s operating capital may not be sufficient to continue some or all of its development programs and operations; the company may decide not to or be unable to file the NDA for SnET2; the FDA may decide not to accept the NDA filing; the FDA may require further clinical or preclinical studies before granting marketing approval, if at all; even if approved, the company may not have the necessary resources or corporate partnering relationship(s) to commercialize the product and the degree of market acceptance will depend upon a number of factors. For a discussion of additional important risk factors that may cause our results to differ from those described above, please refer to our annual report on Form 10-K for the year ended December 31, 2001 and other quarterly and periodic reports filed with the Securities and Exchange Commission. Our products require regulatory approval before marketing, sales or clinical use. PhotoPoint(TM) is a trademark of Miravant Medical Technologies.


--30--MTB/la* HB/la

[Schockeins]

BW0137 JAN 28,2003 9:00 PACIFIC 12:00 EASTERN





( BW)(CA-MIRAVANT)(MRVT) Miravant`s PhotoPoint PDT May Inhibit Failure of Vascular Access Grafts in Hemodialysis Patients

Business Editors/Health & Medical Writers

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Jan. 28, 2003--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical company specializing in PhotoPoint(TM) photodynamic therapy (PDT), today announced novel results for the prevention of vascular access graft failure, which commonly occurs in hemodialysis patients. In two preclinical studies presented at the Cardiovascular Radiation Therapy (CRT) meeting, Washington DC, PhotoPoint PDT significantly inhibited problematic cell proliferation in a synthetic (ePTFE) vascular access graft failure model.
"The results were quite encouraging and, if they can be realized in clinical trials, could make a dramatic difference in our ability to maintain vascular access in hemodialysis patients," stated Julie A. Freischlag, M.D., Chief of Vascular Surgery, UCLA Medical School, whose laboratory participated in the study. "This therapy has the advantage of being locally applied and could make a significant difference in arteriovenous graft failure rates, a major unmet medical problem."
Approximately 250,000 people in the US currently are treated chronically with hemodialysis for kidney failure. Because the hemodialysis procedure requires regular arteriovenous vascular access, a majority of these patients are fitted with synthetic vascular access grafts.

PhotoPoint PDT could favorably impact high failure rates

The failure rate of these synthetic vascular access grafts is 40-60% at twelve months, largely due to cellular proliferation that obstructs blood flow (causes stenosis) and results in occlusive thrombosis. Interventional therapy is required to restore blood flow, typically thrombolytic therapy followed by angioplasty. After the first interventional therapy, grafts fail more frequently and additional interventional procedures are required to maintain graft patency.
PhotoPoint PDT may reduce failure rates by inhibiting this problematic cell growth. Miravant believes these preclinical results support future clinical trials.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is a specialty pharmaceutical company focused on PhotoPoint photodynamic therapy (PDT), a family of medical procedures based on drugs that are activated by light. The company is committed to the discovery and development of proprietary photoselective drugs and innovative light devices for licensing to global pharmaceutical and medical device companies. Miravant is developing PhotoPoint PDT for serious diseases in ophthalmology, dermatology, cardiovascular disease and oncology.

The statements above by Dr. Freischlag and other statements about the potential use of PhotoPoint PDT to treat vascular access grafts are forward-looking and relate to our future plans, objectives, expectations and intentions. Our actual results may differ materially from those described in these statements. For instance, the occurrence of one or more of the following may cause our results to differ from our plans: the results of the company`s preclinical studies may not be indicative of future clinical results when and if the clinical trial process begins; the company`s operating capital may not be sufficient to continue some or all of its development programs and operations; the company may be unable to achieve regulatory approvals for drugs in development; we may decide not to or be unable to further develop PhotoPoint drugs in ophthalmology, dermatology, cardiovascular disease and/or oncology. For a discussion of additional important risk factors that may cause our results to differ from those described above, please refer to our annual report on Form 10-K for the year ended December 31, 2001 and other quarterly and periodic reports filed with the Securities and Exchange Commission. Our products require regulatory approval before marketing, sales or clinical use. PhotoPoint(TM) is a trademark of Miravant Medical Technologies.

For more information, please visit our web site at: www.miravant.com


--30--MRA/la* hb/la MW/la

[Schockeins]

BW0418 JAN 27,2003 9:03 PACIFIC 12:03 EASTERN





( BW)(CA-MIRAVANT-MEDICAL)(MRVT) Miravant`s PhotoPoint PDT Presented at Cardiovascular Conference; Results Support Applications in Vulnerable Plaque, In-Stent Restenosis

Business Editors & Health/Medical Writers

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Jan. 27, 2003--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical company specializing in PhotoPoint(TM) photodynamic therapy (PDT), today announced that preclinical results continue to provide strong support for PhotoPoint PDT as a treatment for serious cardiovascular diseases such as vulnerable plaque (VP) and in-stent restenosis. Miravant is optimizing its catheter-based drug and light treatment for multiple cardiovascular applications. The studies, conducted at the Cardiovascular Research Institute, Washington Hospital Center, were presented at the Cardiovascular Radiation Therapy (CRT 2003) meeting, Washington DC.

Intravascular PhotoPoint PDT may reduce inflammation in vulnerable plaque (VP)

New findings in the disease of atherosclerosis have generated intense interest in the diagnosis and treatment of highly unstable, inflammatory plaque in artery walls known as vulnerable plaque. VP rupture is now recognized as the primary cause of sudden, catastrophic heart attacks and many strokes. Analysts estimate a $10 billion dollar market potential for VP detection and treatment by the end of the decade.
Miravant is developing PhotoPoint therapy in conjunction with emerging diagnostic techniques such as optical coherence imaging and thermography. Encouraging PhotoPoint results were presented at the VP Summit, CRT 2003, demonstrating:


-- Intravascular PhotoPoint PDT induces significant depletion of lipid and macrophage cell populations in arterial plaques in a rabbit atherosclerosis model;
-- PhotoPoint PDT may have positive strengthening effects on the arterial wall via collagen cross-links, a potentially beneficial aspect of this novel therapy.

These findings suggest PhotoPoint`s potential use for reduction of problematic lipid and inflammatory plaque cells, as well as for regression or stabilization of vulnerable plaque without weakening the structural integrity of vessel walls.

Intracoronary PhotoPoint PDT may inhibit restenosis in bare metal stents

Many efforts have been made to resolve the problem of restenosis, or re-narrowing of an artery following angioplasty and stenting. Recently, new drug coated stent technology utilizing rapamycin has shown dramatic prevention of in-stent restenosis at 6-9 months in selected patients. However, other drug-stent combinations have failed to show long term benefit. Furthermore, this approach has generated new concerns such as prohibitive costs for multivessel disease as well as other potential complications. Thus Miravant examined the effects of PhotoPoint PDT to prevent in-stent restenosis following implantation of bare metal stents.
Promising findings were presented at the Restenosis Forum, CRT 2003:

-- Intracoronary PhotoPoint PDT inhibits cellular proliferation
in a porcine coronary model of in-stent restenosis;

-- PhotoPoint PDT allows normal arterial healing (endothelial
regeneration).

These data support the feasibility of using PhotoPoint PDT in combination with stenting, which is currently used in 80% of de novo lesions. Consequently, PhotoPoint may provide a viable, cost-effective alternative anti-restenotic therapy to drug-eluting stents for multivessel disease.

About Miravant

Miravant Medical Technologies, based in Santa Barbara, Calif., is a specialty pharmaceutical company focused on PhotoPoint Photodynamic Therapy (PDT), a family of medical procedures based on drugs that are activated by light. The company is committed to the discovery and development of proprietary photoselective drugs and innovative light devices for licensing to global pharmaceutical and medical device companies. Miravant is developing PhotoPoint PDT for serious diseases in ophthalmology, dermatology, cardiovascular disease and oncology.

The statements above about the potential use of PhotoPoint PDT to treat serious cardiovascular diseases including vulnerable plaque and in-stent restenosis are forward-looking and relate to our future plans, objectives, expectations and intentions. Our actual results may differ materially from those described in these statements. For instance, the occurrence of one or more of the following may cause our results to differ from our plans: the results of the company`s preclinical studies may not be indicative of future results when and if the clinical trial process begins; the company`s operating capital may not be sufficient to continue some or all of its development programs and operations; analyst estimates of VP market potential may change with time due to a number factors; the company may be unable to achieve regulatory approvals for drugs in development; we may decide not to or be unable to further develop PhotoPoint drugs in ophthalmology, dermatology, cardiovascular disease and/or oncology. For a discussion of additional important risk factors that may cause our results to differ from those described above, please refer to our annual report on Form 10-K for the year ended December 31, 2001 and other quarterly and periodic reports filed with the Securities and Exchange Commission. Our products require regulatory approval before marketing, sales or clinical use. PhotoPoint(TM) is a trademark of Miravant Medical Technologies.

For more information, please visit our web site at: www.miravant.com.